• ShareThis
  • Print
  • Text Size

European Association for the Study of Diabetes (EASD) 2009

C-peptide Correction Method to Determine Exogenous Insulin Levels in Pharmacokinetic Studies Using Technosphere® Insulin

C-peptide Abstract

C-peptide Poster

Inhaled GLP-1 and Exenatide: Different Effects on Pancreatic and Gastric Activity Following a Single Dose in Type 2 Diabetes Mellitus

Inhaled GLP-1 Effects on Pancreatic and Gastric Activity Abstract

Inhaled GLP-1 Effects on Pancreatic and Gastric Activity Poster

Response to Inhaled GLP-1 is Dependent on Baseline Glucose

Response to Inhaled GLP-1 Abstract

Response to Inhaled GLP-1 Poster

Basal/Bolus With Prandial Inhaled Technosphere® Insulin (TI) Plus Insulin Glargine QD vs Biaspart 70/30 Insulin BID in T2 DM Inadequately Controlled on Insulin With/Without Oral Agents

Basal/Bolus With Prandial Inhaled Technosphere® Insulin (TI) Abstract

Basal/Bolus With Prandial Inhaled Technosphere® Insulin (TI) Poster

Reduced Incidence and Frequency of Hypoglycemia in an Integrated Analysis of Pooled Data from Clinical Trials of Subjects with Type 2 Diabetes Using Prandial Inhaled Technosphere® Insulin

Clinical Trials of Subjects with Type 2 Diabetes Abstract

Clinical Trials of Subjects with Type 2 Diabetes Poster

Pulmonary Function Tests Remain Similar in Patients Who Received Technosphere® Insulin and in Patients Currently Receiving Standard Antidiabetic Therapy

Patients Currently Receiving Standard Antidiabetic Therapy Abstract

Patients Currently Receiving Standard Antidiabetic Therapy Poster

Pulmonary Functions (Over 2 Years) in Diabetic Subjects Treated with Technosphere® Insulin or Usual Antidiabetic Treatment

Diabetic Subjects Treated with Technosphere® Insulin Abstract

Diabetic Subjects Treated with Technosphere® Insulin Poster

Pulmonary Safety of Inhaled Technosphere® Insulin Therapy in Adults with Diabetes Using High-Resolution Computerized Tomography of the Chest

Pulmonary Safety of Inhaled Technosphere® Insulin Abstract

Pulmonary Safety of Inhaled Technosphere® Insulin Poster

Technosphere® Insulin Suppresses Endogenous Glucose Production Earlier Than a Rapid-Acting Analog (Lispro) and an Inhaled Insulin (Exubera)

Technosphere® Insulin Suppresses Endogenous Glucose Abstract

Technosphere® Insulin Suppresses Endogenous Glucose Poster

Pharmacokinetics of Technosphere® Insulin Unchanged in Patients with Chronic Obstructive Pulmonary Disease

Pharmacokinetics of Technosphere® Insulin Abstract

Pharmacokinetics of Technosphere® Insulin Poster

Lung Deposition and Absorption of Insulin from Technosphere® Insulin

Lung Deposition and Absorption of Insulin Abstract

Lung Deposition and Absorption of Insulin Poster

Comparative Efficacy and Safety of Technosphere® Insulin and a Rapid-Acting Analog Both Given With Glargine in Subjects with T1 DM in a 52-Week Study

Comparative Efficacy and Safety of Technosphere® Insulin Abstract

Comparative Efficacy and Safety of Technosphere® Insulin Poster

Reduced Incidence and Frequency of Hypoglycemia in an Integrated Analysis of Pooled Data from Clinical Trials of Subjects with Type 1 Diabetes Using Prandial Inhaled Technosphere® Insulin

Reduced Incidence and Frequency of Hypoglycemia Abstract

Reduced Incidence and Frequency of Hypoglycemia Poster

Patient Reported Outcomes in Adults with Type 2 Diabetes Using Mealtime Insulin Monomer Human (rDNA origin) Inhalation Powder (Technosphere® Insulin Inhalation Powder) or Metformin + Secretagogue or Both

Patient Reported Outcomes in Adults with Type 2 Diabetes Abstract

Patient Reported Outcomes in Adults with Type 2 Diabetes Poster

Long-term Sustained Safety and Efficacy of Continued Use of Technosphere® Insulin in Subjects with Type 2 Diabetes (Oral Presentation)

Long-term Sustained Safety and Efficacy Abstract